Product image of Letrofar (Letrozole) supplied by GNH India

Letrofar

Active Ingredient:
Letrozole
Origin:
EU

Letrofar (Letrozole)

Letrozole, the active ingredient in Letrofar, is an aromatase inhibitor presented as an oral tablet for oral use. It treats postmenopausal estrogen receptor‑positive breast cancer by lowering estrogen levels that fuel tumor growth. The drug complies with EU pharmaceutical standards and is supplied in a quality‑controlled formulation.

GNH India supplies Letrofar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Makpharm D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Letrozole is an aromatase inhibitor used in the endocrine treatment of hormone‑dependent breast cancer.
  • Postmenopausal estrogen receptor‑positive breast cancer: reduces risk of disease recurrence and progression.
  • Advanced/metastatic breast cancer in postmenopausal women: slows tumor growth and extends survival.
  • Adjuvant therapy after surgery in hormone‑responsive breast cancer: helps prevent cancer return.
  • Neoadjuvant treatment of locally advanced breast cancer: may shrink tumor before surgery.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme, blocking the conversion of adrenal and ovarian androgens into estrogens. This leads to markedly reduced circulating estrogen concentrations, depriving estrogen‑dependent breast cancer cells of a growth stimulus and thereby inhibiting tumor proliferation.

Side Effects

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth, often with sweating.
  • Joint and muscle pain: arthralgia or myalgia.
  • Fatigue: persistent tiredness.
  • Nausea: upset stomach.

Serious or Rare Side Effects

  • Severe liver injury: jaundice or markedly elevated enzymes.
  • Bone fractures: increased risk due to reduced bone mineral density.
  • Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
  • Allergic reactions: rash, swelling, or anaphylaxis.

Precautions & Warnings

  • When prescribing Letrofar, clinicians should consider several safety measures.
  • Monitor bone health: assess calcium and vitamin D status regularly.
  • Assess cardiovascular risk: review history of heart disease or thrombotic disorders.
  • Check liver function: obtain baseline hepatic enzyme measurements.
  • Avoid use in premenopausal women: drug is not indicated for this population.
  • Pregnancy and lactation: contraindicated due to unknown safety.
  • Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Avoid Interactions

Letrofar can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Concurrent estrogen replacement therapy: diminishes Letrofar efficacy.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations.
  • Tamoxifen: antagonistic effect on estrogen pathways.
  • Warfarin: potential increase in anticoagulant effect.

Moderate Interactions (Monitor Closely)

  • Selective serotonin reuptake inhibitors: possible additive bone‑loss risk.
  • Statins: monitor lipid profile for changes.
  • Certain antidepressants (e.g., venlafaxine): may exacerbate hot flashes.

Frequently Asked Questions

Letrofar contains letrozole, an aromatase inhibitor indicated for the treatment of postmenopausal women with estrogen receptor‑positive breast cancer. It is used in both early‑stage (adjuvant) and advanced or metastatic disease to reduce tumor growth driven by estrogen.

Letrozole works by reversibly inhibiting the aromatase enzyme, which converts androgens into estrogens. By blocking this conversion, circulating estrogen levels fall dramatically, depriving hormone‑sensitive breast cancer cells of the estrogen needed for proliferation.

The dose of letrozole is individualized by the prescribing clinician based on the patient’s condition, renal and hepatic function, and other therapies. The prescriber determines the appropriate regimen and any dose adjustments.

Safety of letrozole during pregnancy or lactation has not been established. The product is contraindicated in pregnant or nursing women, and effective contraception is recommended for women of child‑bearing potential while on therapy.

To order Letrofar, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrofar (letrozole) and anastrozole are both third‑generation aromatase inhibitors with similar efficacy in postmenopausal breast cancer. Letrozole is often preferred for its slightly higher potency, whereas anastrozole may be chosen based on tolerability, drug‑interaction profile or clinician experience.

Letrofar should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the tablets in the original blister pack until use and avoid storing in humid or excessively hot environments.

Letrofar is administered orally as a tablet, usually taken once daily with water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Serious risks include severe liver injury, increased risk of bone fractures due to reduced bone density, thromboembolic events such as deep‑vein thrombosis, and rare but potentially life‑threatening allergic reactions. Patients should report any signs of jaundice, severe bone pain, swelling of the legs or rash promptly.

Letrofar should not be used in premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or those with known hypersensitivity to letrozole or any excipients in the tablet. Caution is also advised for patients with a history of cardiovascular disease or osteoporosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT